skip to main content
Resource type Show Results with: Show Results with: Search type Index

Profile of lacosamide and its role in the long-term treatment of epilepsy: a perspective from the updated NICE guideline

Nunes, Vanessa Delgado ; Sawyer, Laura ; Neilson, Julie ; Sarri, Grammati ; Cross, J Helen

Neuropsychiatric disease and treatment, 2013, Vol.9, p.467-476 [Peer Reviewed Journal]

Full text available

Citations Cited by
  • Title:
    Profile of lacosamide and its role in the long-term treatment of epilepsy: a perspective from the updated NICE guideline
  • Author: Nunes, Vanessa Delgado ; Sawyer, Laura ; Neilson, Julie ; Sarri, Grammati ; Cross, J Helen
  • Subjects: Laws, regulations and rules ; Epilepsy ; Lacosamide ; Practice guidelines (Medicine) ; Dosage and administration ; Administrative agencies ; Drug therapy ; Convulsions & seizures ; focal seizures ; clinical guideline ; adjunctive therapy ; anti-epileptic drug ; Review
  • Is Part Of: Neuropsychiatric disease and treatment, 2013, Vol.9, p.467-476
  • Description: The goal of antiepileptic treatment is to achieve seizure freedom or seizure control. The aim of this paper is to review the evidence for the use of lacosamide for adjunctive treatment of refractory focal seizures with or without secondary generalization, within the scope of the 2012 update of the Clinical Guideline published by the National Institute for Health and Clinical Excellence (NICE). Clinical evidence for the use of lacosamide and other antiepileptic drugs (AEDs) was systematically reviewed, evaluated, and presented to the Guideline Development Group. Only randomized clinical trials were included. Outcomes of clinical efficacy (seizure freedom, 50% reduction in seizure frequency, time to first seizure, time to 12-month remission, treatment withdrawal, and time to treatment withdrawal), experience of adverse events, and cognitive and quality of life outcomes were reviewed. A decision model was built to weigh the clinical benefits of each adjunctive AED, measured by seizure control and seizure reduction, compared with the harm from adverse events, as measured by withdrawals from treatment due to adverse events. Lacosamide was included as part of the recommended AEDS to be used in tertiary epilepsy centers. The evidence review showed that more participants who received lacosamide as an adjunctive treatment had at least a 50% reduction in seizure frequency compared with those taking placebo. However, more participants on lacosamide were found to experience adverse events and withdrawal from treatment compared with those on placebo. The cost-effectiveness analysis showed that compared with placebo, the benefits gained from adjunctive lacosamide were modest and uncertain, whereas the costs were significantly high. Compared with other AEDs licensed for adjunctive therapy in focal seizures, lacosamide was associated with fewer quality-adjusted life years and higher costs. Therefore, the Guideline Development Group noted that the balance of benefit and harm needs to be carefully monitored in all patients.
  • Publisher: New Zealand: Dove Medical Press Limited
  • Language: English
  • Identifier: ISSN: 1176-6328
    EISSN: 1178-2021
    DOI: 10.2147/NDT.S32081
    PMID: 23630422
  • Source: © ProQuest LLC All rights reserved

Searching Remote Databases, Please Wait